Efficacy of Intravitreal Dexamethasone Implant (Ozurdex®) in Naïve and Refractory Patients with Different Morphological Subtypes of Diabetic Macular Edema.

IF 2.4 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Panagiotis Stavrakas, Evita Evangelia Christou, Vasileios Nasikas, Chrysoula Koutsiouki, Athanasios Vakalis, Solon Asteriadis, Georgios D Panos, Paris Tranos
{"title":"Efficacy of Intravitreal Dexamethasone Implant (Ozurdex<sup>®</sup>) in Naïve and Refractory Patients with Different Morphological Subtypes of Diabetic Macular Edema.","authors":"Panagiotis Stavrakas, Evita Evangelia Christou, Vasileios Nasikas, Chrysoula Koutsiouki, Athanasios Vakalis, Solon Asteriadis, Georgios D Panos, Paris Tranos","doi":"10.3390/medicina61030488","DOIUrl":null,"url":null,"abstract":"<p><p><i>Background and Objectives</i>: To investigate anatomical and functional outcomes in different morphological subtypes of diabetic macular edema (DME) treated with an intravitreal dexamethasone implant (Ozurdex) over 6 months follow-up. <i>Materials and Methods</i>: A retrospective, comparative study on patients with DME who received an intravitreal dexamethasone implant. Best-corrected visual acuity (BCVA), central subfoveal thickness (CST) and maximum CST on optical coherence tomography (OCT) were measured. The recruits were divided into three groups based on the morphological patterns of DME: serous retinal detachment (SRD), cystic macular edema (CME) and diffuse retinal thickening (DRT). The presence or absence of previous treatment were considered as being previously treated with anti-VEGF (PT) vs. naïve eyes (TN). All subjects received a single injection of the dexamethasone implant. The primary outcomes included changes in BCVA, CST and CSTMax at 2-, 4- and 6-months of follow-up. <i>Results</i>: CST was significantly reduced following one dexamethasone injection in the whole cohort from a total mean value of 513.3 μm to 368.2 μm at 2 months, 447.2 μm at 4 months and 471.5 μm at 6 months. The change in CST was significantly greater in SRD as opposed to the DRT and CME group at all time points. Overall, BCVA improved from 0.82 at baseline to 0.75 and 0.76 LogMAR at 2 and 4 months, respectively, whilst showing an overall deterioration to 0.84 at 6 months. The CME group showed the best BCVA at 6 months. Concerning treatment status (TN vs. PT), there was no significant difference in CST at 2 and 4 months, while CST was reduced at 6 months for the PT group (<i>p</i> = 0.023). Similarly, BCVA was significantly better in the PT group at 6 months (<i>p</i> = 0.017). <i>Conclusions</i>: The dexamethasone implant was effective in reducing DME and providing short-term BCVA improvement. The presence of SRD was associated with more favorable anatomical results, while CME was associated with better visual acuity. Dexamethasone provided superior results in previously treated patients.</p>","PeriodicalId":49830,"journal":{"name":"Medicina-Lithuania","volume":"61 3","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11943906/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina-Lithuania","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/medicina61030488","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Objectives: To investigate anatomical and functional outcomes in different morphological subtypes of diabetic macular edema (DME) treated with an intravitreal dexamethasone implant (Ozurdex) over 6 months follow-up. Materials and Methods: A retrospective, comparative study on patients with DME who received an intravitreal dexamethasone implant. Best-corrected visual acuity (BCVA), central subfoveal thickness (CST) and maximum CST on optical coherence tomography (OCT) were measured. The recruits were divided into three groups based on the morphological patterns of DME: serous retinal detachment (SRD), cystic macular edema (CME) and diffuse retinal thickening (DRT). The presence or absence of previous treatment were considered as being previously treated with anti-VEGF (PT) vs. naïve eyes (TN). All subjects received a single injection of the dexamethasone implant. The primary outcomes included changes in BCVA, CST and CSTMax at 2-, 4- and 6-months of follow-up. Results: CST was significantly reduced following one dexamethasone injection in the whole cohort from a total mean value of 513.3 μm to 368.2 μm at 2 months, 447.2 μm at 4 months and 471.5 μm at 6 months. The change in CST was significantly greater in SRD as opposed to the DRT and CME group at all time points. Overall, BCVA improved from 0.82 at baseline to 0.75 and 0.76 LogMAR at 2 and 4 months, respectively, whilst showing an overall deterioration to 0.84 at 6 months. The CME group showed the best BCVA at 6 months. Concerning treatment status (TN vs. PT), there was no significant difference in CST at 2 and 4 months, while CST was reduced at 6 months for the PT group (p = 0.023). Similarly, BCVA was significantly better in the PT group at 6 months (p = 0.017). Conclusions: The dexamethasone implant was effective in reducing DME and providing short-term BCVA improvement. The presence of SRD was associated with more favorable anatomical results, while CME was associated with better visual acuity. Dexamethasone provided superior results in previously treated patients.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Medicina-Lithuania
Medicina-Lithuania 医学-医学:内科
CiteScore
3.30
自引率
3.80%
发文量
1578
审稿时长
25.04 days
期刊介绍: The journal’s main focus is on reviews as well as clinical and experimental investigations. The journal aims to advance knowledge related to problems in medicine in developing countries as well as developed economies, to disseminate research on global health, and to promote and foster prevention and treatment of diseases worldwide. MEDICINA publications cater to clinicians, diagnosticians and researchers, and serve as a forum to discuss the current status of health-related matters and their impact on a global and local scale.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信